Therapeutic clinical evaluation of the Plectranthus amboinicus Lour Spreng (Oregano French) tablets in patient with common cold

Phase 1

Recruiting

Conditions: Common cold

Registration Number: RPCEC00000124

Lead Sponsor: Drug Research and Development Center (CIDEM)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 90

Inclusion Criteria

1. Patient bigger than 18 years of age. 2. Written consent of patient 3. Patient with cough and expectoration of less than 14 days. 4. Negative Leucogram, with or without altered lymphocytes.

Exclusion Criteria

1. Pregnancy or breastfeeding. 2. Not meet any criteria for inclusion. 3. Patients with ERC Chronic disorders: Asthma, EPOC, bronquiectasias 4. Ingestion of medications: steroids, antipsicóticos habitually. 5. Ingestion of antibiotics, broncodilatadores, during one previous month. 6. Cough originated by adverse effect to the IECA or foreign bodies. 7. Patients with presence of sputum purulento, serous or bloody. 8. Patients with presence of humid stertors in the physical test. 9. Patients with decompensated Chronic disorders not transmissible. 10.Patients with any neurological or systemic disorder affecting the nervous system. 11.HIV.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of the cough in 24 hours (0 - Non cough, 1 - of 1 to 4 times, 2 - of 5 to 10 times, 3 - of 11 at 15 times and 4 - more than 15 times). Measuring time: 3, 7 and 15 days. Intensity of the cough in 24 hours (Slight: less than 5 accesses of cough and it can accompany of expectoration. Moderate: More than 5 accesses of cough and less than 10. Severe: More than 10 accesses of cough). Measuring time: 3, 7 and 15 days. Expectoration presence. (Yes/No).Measuring time: 3, 7 and 15 days.

Secondary Outcome Measures

Name	Time	Method
Adverse events (Description, Intensity, Duration). Measuring time: 15 days. Description of the adverse event (Name) Intensity of the adverse event (Light, Moderate, Severe) Duration of the adverse event. (differs of date among the beginning and final of the event)